Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Britton Boras

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Pharmaceutical Research|September 22, 2012
Nanoparticles for improved local retention after intra-articular injection into the knee jointMichael Morgen, David Tung, Britton Boras, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 1, 2021
A whole-body circulatory neutrophil model with application to predicting clinical neutropenia from in vitro studiesWenbo Chen, Britton Boras, Tae Sung, et al.
The AAPS Journal|November 6, 2020
Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical TranslationWenbo Chen, Britton Boras, Tae Sung, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 23, 2025
Identification of oncology pharmacokinetic drivers through in vitro experiments and computational modelingBritton Boras, Eric C Greenwald, Yuli Wang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 13, 2020
A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitorWenbo Chen, Britton Boras, Tae Sung, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 20, 2026
Absorption, distribution, metabolism, and excretion tactics toward the expedited discovery and development of the severe acute respiratory syndrome coronavirus-2 main protease inhibitor nirmatrelvirAmit S Kalgutkar, Heather Eng, Alyssa L Dantonio, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 16, 2024
Quantitative systems toxicology modeling in pharmaceutical research and development: An industry-wide survey and selected case study examplesKylie A Beattie, Meghna Verma, Richard J Brennan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 14, 2022
Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and HumansHeather Eng, Alyssa L Dantonio, Eugene P Kadar, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 11, 2022
Current practices for QSP model assessment: an IQ consortium surveyJason R Chan, Richard Allen, Britton Boras, et al.
Molecular Cancer Therapeutics|March 21, 2025
18F-FLT PET, a Non-Invasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin Dependent Kinase (CDK) InhibitorsAnand Giddabasappa, Ziyue Karen Jiang, Bing Yang, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Pharmaceutical Research|September 22, 2012
Nanoparticles for improved local retention after intra-articular injection into the knee jointMichael Morgen, David Tung, Britton Boras, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 1, 2021
A whole-body circulatory neutrophil model with application to predicting clinical neutropenia from in vitro studiesWenbo Chen, Britton Boras, Tae Sung, et al.
The AAPS Journal|November 6, 2020
Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical TranslationWenbo Chen, Britton Boras, Tae Sung, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 23, 2025
Identification of oncology pharmacokinetic drivers through in vitro experiments and computational modelingBritton Boras, Eric C Greenwald, Yuli Wang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 13, 2020
A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitorWenbo Chen, Britton Boras, Tae Sung, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 20, 2026
Absorption, distribution, metabolism, and excretion tactics toward the expedited discovery and development of the severe acute respiratory syndrome coronavirus-2 main protease inhibitor nirmatrelvirAmit S Kalgutkar, Heather Eng, Alyssa L Dantonio, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 16, 2024
Quantitative systems toxicology modeling in pharmaceutical research and development: An industry-wide survey and selected case study examplesKylie A Beattie, Meghna Verma, Richard J Brennan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 14, 2022
Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and HumansHeather Eng, Alyssa L Dantonio, Eugene P Kadar, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 11, 2022
Current practices for QSP model assessment: an IQ consortium surveyJason R Chan, Richard Allen, Britton Boras, et al.
Molecular Cancer Therapeutics|March 21, 2025
18F-FLT PET, a Non-Invasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin Dependent Kinase (CDK) InhibitorsAnand Giddabasappa, Ziyue Karen Jiang, Bing Yang, et al.
Pageof 2